Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 30.
doi: 10.1097/HEP.0000000000001444. Online ahead of print.

Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab

Heechul Nam  1   2 , Dong Yun Kim  3 , Do Young Kim  3 , Ji Hoon Kim  1   2 , Chang Wook Kim  1   2 , Jaejun Lee  1   4 , Keungmo Yang  1   4 , Ji Won Han  1   4 , Pil Soo Sung  1   4 , Seung Kew Yoon  1   4 , Hee Sun Cho  1   5 , Hyun Yang  1   5 , Si Hyun Bae  1   5 , Soon Kyu Lee  1   6 , Jung Hyun Kwon  1   6 , Soon Woo Nam  1   6 , Ahlim Lee  1   7 , Do Seon Song  1   7 , U Im Chang  1   7 , Seok-Hwan Kim  1   8 , Myeong Jun Song  1   8 , Hae Lim Lee  1   9 , Hee Yeon Kim  1   9 , Sung Won Lee  1   9 , Jeong Won Jang  1   4
Affiliations

Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab

Heechul Nam et al. Hepatology. .

Abstract

Background and aims: Atezolizumab plus bevacizumab (AB) has become the standard first-line treatment for advanced HCC. However, identifying reliable prognostic biomarkers remains a critical challenge. We aimed to develop a comprehensive scoring system to predict overall survival (OS) in advanced HCC patients receiving first-line AB.

Approach and results: We included patients with advanced HCC receiving first-line AB from multiple centers in Korea, forming a derivation cohort ( n =456) and a validation cohort ( n =205). Multivariable analysis identified 5 independent prognostic factors: C-reactive protein ≥1.0 mg/dL (HR 2.07; p <0.001), albumin <3.5 g/dL (HR 1.60; p =0.002), protein induced by vitamin K absence or antagonist-II ≥1500 mAU/mL (HR 1.60; p =0.002), total bilirubin ≥1.0 mg/dL (HR 1.50; p =0.006), and macrovascular invasion (HR 1.49; p =0.009). We developed the CRAPT-M model, named after these factors' initial letters. Patients were categorized into low (≤4), intermediate (5-12), and high (≥13) risk groups by CRAPT-M score. Median OS differed significantly: 22.4 (95% CI, 18.6-25.0), 12.9 (95% CI, 8.7-14.8), and 6.7 (95% CI, 5.1-7.7) months for low-risk, intermediate-risk, and high-risk groups, respectively ( p <0.001). Time-dependent area under the receiver operating characteristic for CRAPT-M demonstrated consistently higher predictive accuracy than the CRAFITY model, with values of 0.785, 0.737, and 0.742 at 12, 24, and 36 months, respectively. The model demonstrated robust predictive performance in the external validation cohort, with excellent calibration and consistent discrimination across sensitivity analyses.

Conclusions: The CRAPT-M model demonstrated robust OS prediction, offering a valuable tool for prognosis estimation and clinical decision-making in advanced HCC patients receiving AB.

Keywords: C-reactive protein; HCC; immuno-oncology; risk prediction model.

PubMed Disclaimer

References

    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
    1. Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598–606.
    1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.
    1. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862–73.
    1. Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - Development and validation of the CRAFITY score. J Hepatol. 2022;76:353–63.

LinkOut - more resources